Isavuconazole: A comprehensive review of spectrum of activity of a new triazole

George R. Thompson; Nathan P. Wiederhold

doi:10.1007/s11046-010-9324-3

Isavuconazole: A comprehensive review of spectrum of activity of a new triazole

George R. Thompson, Nathan P. Wiederhold

Department of Pathology

Research output: Contribution to journal › Review article › peer-review

118 Scopus citations

Abstract

Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

Original language	English (US)
Pages (from-to)	291-313
Number of pages	23
Journal	Mycopathologia
Volume	170
Issue number	5
DOIs	https://doi.org/10.1007/s11046-010-9324-3
State	Published - Nov 2010

Keywords

Antifungal
Fungicidal
Fungistatic
In vitro activity
In vivo studies
Isavuconazole

ASJC Scopus subject areas

Applied Microbiology and Biotechnology
Agronomy and Crop Science
veterinary (miscalleneous)
Microbiology

Access to Document

10.1007/s11046-010-9324-3

Cite this

@article{c5e04e041fb84499902d8e8cfb8ba308,

title = "Isavuconazole: A comprehensive review of spectrum of activity of a new triazole",

abstract = "Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.",

keywords = "Antifungal, Fungicidal, Fungistatic, In vitro activity, In vivo studies, Isavuconazole",

author = "Thompson, {George R.} and Wiederhold, {Nathan P.}",

year = "2010",

month = nov,

doi = "10.1007/s11046-010-9324-3",

language = "English (US)",

volume = "170",

pages = "291--313",

journal = "Mycopathologia",

issn = "0301-486X",

publisher = "Springer Netherlands",

number = "5",

}

TY - JOUR

T1 - Isavuconazole

T2 - A comprehensive review of spectrum of activity of a new triazole

AU - Thompson, George R.

AU - Wiederhold, Nathan P.

PY - 2010/11

Y1 - 2010/11

N2 - Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

AB - Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

KW - Antifungal

KW - Fungicidal

KW - Fungistatic

KW - In vitro activity

KW - In vivo studies

KW - Isavuconazole

UR - http://www.scopus.com/inward/record.url?scp=78049352249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049352249&partnerID=8YFLogxK

U2 - 10.1007/s11046-010-9324-3

DO - 10.1007/s11046-010-9324-3

M3 - Review article

C2 - 20524153

AN - SCOPUS:78049352249

SN - 0301-486X

VL - 170

SP - 291

EP - 313

JO - Mycopathologia

JF - Mycopathologia

IS - 5

ER -

Isavuconazole: A comprehensive review of spectrum of activity of a new triazole

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this